TY - JOUR
T1 - Outcome after mastectomy for ipsilateral breast tumor recurrence after breast conserving surgery
AU - Beard, H. Randall
AU - Cantrell, Emily F.
AU - Russell, Gregory B.
AU - Howard-McNatt, Marissa
AU - Shen, Perry
AU - Levine, Edward A.
PY - 2010/8
Y1 - 2010/8
N2 - Ipsilateral breast tumor recurrence (IBTR) is a risk after breast conserving surgery, and is traditionally treated with mastectomy. Given the limited literature on outcome after mastectomy for IBTR, we evaluated our long-term data for this group. A retrospective review was conducted using a database of 2101 breast cancer patients at a single institution. Fifty-nine patients underwent breast conserving surgery and experienced an IBTR. Exclusion criteria included repeat lumpectomy or metastatic disease before mastectomy. Patients presented with invasive ductal (58%), invasive lobular (7%), other invasive (11%), or ductal carcinoma in situ (24%). Initial tumors were Tis (24%), T1 (42%), T2 (20%), T3 (2%), or not recorded (12%). IBTR lesions were Tis (20%), T1 (46%), T2 (25%), or T3 (9%). Median follow-up after mastectomy was 4.6 years. Thirteen patients (22%) had post-mastectomy recurrence (PMR), which decreased overall survival (P = 0.002). PMR was more common with larger IBTR tumors (P = 0.03), specifically IBTR ≥ T2 (P = 0.003). Eighty-five per cent of PMR occurred within 2 years of mastectomy. Mastectomy for IBTR remains effective treatment for most patients, but the risk of PMR remains. Patients with IBTR tumors >2 cm have an increased risk of PMR. Strict follow-up should be routine, especially during the first 24 months.
AB - Ipsilateral breast tumor recurrence (IBTR) is a risk after breast conserving surgery, and is traditionally treated with mastectomy. Given the limited literature on outcome after mastectomy for IBTR, we evaluated our long-term data for this group. A retrospective review was conducted using a database of 2101 breast cancer patients at a single institution. Fifty-nine patients underwent breast conserving surgery and experienced an IBTR. Exclusion criteria included repeat lumpectomy or metastatic disease before mastectomy. Patients presented with invasive ductal (58%), invasive lobular (7%), other invasive (11%), or ductal carcinoma in situ (24%). Initial tumors were Tis (24%), T1 (42%), T2 (20%), T3 (2%), or not recorded (12%). IBTR lesions were Tis (20%), T1 (46%), T2 (25%), or T3 (9%). Median follow-up after mastectomy was 4.6 years. Thirteen patients (22%) had post-mastectomy recurrence (PMR), which decreased overall survival (P = 0.002). PMR was more common with larger IBTR tumors (P = 0.03), specifically IBTR ≥ T2 (P = 0.003). Eighty-five per cent of PMR occurred within 2 years of mastectomy. Mastectomy for IBTR remains effective treatment for most patients, but the risk of PMR remains. Patients with IBTR tumors >2 cm have an increased risk of PMR. Strict follow-up should be routine, especially during the first 24 months.
UR - http://www.scopus.com/inward/record.url?scp=77956202955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956202955&partnerID=8YFLogxK
M3 - Article
C2 - 20726412
AN - SCOPUS:77956202955
SN - 0003-1348
VL - 76
SP - 829
EP - 834
JO - American Surgeon
JF - American Surgeon
IS - 8
ER -